Clinical Trial: Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea
Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional
Official Title: Single Daily Dose Rifaximin vs. Standard Thrice Daily Dosing for the 3-Day Treatment of Travelers' Diarrhea
Brief Summary:
The study will compare durations of diarrhea among subjects who report to clinic for treatment and who receive either:
- standard rifaximin therapy at a dose of 200 mg three times a day for 3 days, OR
- a single 600 mg dose of rifaximin daily for 3 days.
Detailed Summary:
Sponsor: The University of Texas Health Science Center, Houston
Current Primary Outcome: Time from beginning therapy to passage of last unformed stool [ Time Frame: 5 days ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Side effects as reported by the subjects on diaries [ Time Frame: 5 days ]
Original Secondary Outcome: Same as current
Information By: The University of Texas Health Science Center, Houston
Dates:
Date Received: April 3, 2009
Date Started: June 2009
Date Completion: June 2009
Last Updated: June 8, 2015
Last Verified: June 2015
